A novel temporary peripheral nerve stimulation system that delivers electrical stimulation therapy in a cubital tunnel release model will be evaluated for feasibility.

This study aims to evaluate how sarcoma-specific educational videos improve patients' knowledge of their disease and treatment options before their first clinic appointment. Participants will watch four educational videos before their first appointment with a medical oncologist. Participants will be asked to complete surveys to assess their understanding of sarcoma and its treatment options before and after their first medical oncology clinic appointment.

Some people's ascending aorta (As.A) can become enlarged, increasing the risk of tearing/rupture. This can be highly fatal, despite surgical intervention. The size of aorta where surgical vs surveillance recommendations are grey is between 5.0 to 5.4 cm. In this trial, patients with a 5.0 to 5.4 cm As.A, will be randomly assigned to either early surgical intervention or the surveillance group. Results of this trial will guide future practice for patients with enlarged AS.A, specifically the 5.0-5.4 cm size, since the guidance on how to manage this group of patients is not concrete.  Enrolling in a registry is also an option if one does not want to participate in the main randomized trial.

Perioperative respiratory complications are a major source of morbidity and mortality. Postoperative atelectasis plays a central role in their development. Protective "open lung" mechanical ventilation aims to minimize the occurrence of atelectasis during the perioperative period. Randomized controlled studies have been performed comparing various "open lung" ventilation protocols, but these studies report varying and conflicting effects. The interpretation of these studies is complicated by the absence of imagery supporting the pulmonary impact associated with the use of different ventilation strategies. Imaging studies suggest that the gain in pulmonary gas content in "open lung" ventilation regimens disappears within minutes after the extubation. Thus, the potential benefits of open-lung ventilation appear to be lost if, at the time of extubation, no measures are used to keep the lungs well aerated. Recent expert recommendations on good mechanical ventilation practices in the operating room conclude that there is actually no quality study on extubation. Extubation is a very common practice for anesthesiologists as part of their daily clinical practice. It is therefore imperative to generate evidence on good clinical practice during anesthetic emergence in order to potentially identify an effective extubation strategy to reduce postoperative pulmonary complications.

This goal of this study is to analyze images of the right ventricle taken via 3D transesophageal echocardiography (TEE) during left ventricular assist device (LVAD) implantation.

The purpose of this study is to compare the efficacy and safety of risankizumab versus vedolizumab over 48 weeks to compare how well these drugs work in patients with moderate to severe Ulcerative Colitis (UC). Both study drugs risankizumab and vedolizumab are currently approved in multiple countries for the treatment of adults with moderate to severe Ulcerative Colitis (UC) and Crohn’s disease(CD). You have been diagnosed with UC disease and are experiencing symptoms such as diarrhea with or without blood, abdominal pain and/or a sudden and constant feeling that you have to move your bowels. Additionally, you have been never treated with some medications that help reduce the inflammation associated with your disease that are referred to as targeted therapies. Risankizumab is made in the laboratory and is a monoclonal antibody which means that it is the same as a protein in your body, called an antibody. It works by blocking the actions of a protein known as Interleukin 23. Interleukin 23 is involved in the immune response and plays an important role in the development of chronic inflammation. Risankizumab is currently approved in multiple countries for the treatment of adults with moderate to severe UC and CD. Vedolizumab is a monoclonal antibody which is directed against the α4β7 heterodimer which is expressed on most leucocytes (a type of blood cell that is made in the bone marrow and found in the blood and lymph tissue) and is important for migration of leucocytes to gut-associated lymphoid tissues. Vedolizumab is approved in multiple countries for both moderately to severely active UC and CD.

The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.

The goal of the study is to learn about the safety of Sacituzumab Tirumotecan and if people can tolerate it when given in the bladder and find the highest dose that people can take without having certain problems. Researchers will then choose a dose level of Sacituzumab Tirumotecan to use in future studies to learn how well the drug works.

NOTE: To participate in this study, you must have a permanent pacemaker (PPM) or implantable cardioverter-defibrillator (ICD) that is capable of remote monitoring. Remote monitoring is in widespread use worldwide, but in Canada, it is used primarily in patients with ICDs, not pacemakers. It is cost-effective and can reduce the detection times of potential cardiac problems. What is Remote Monitoring Technology? The remote monitoring technology will communicate with your implantable device using wireless technology. It sends the information from your pacemaker to an application on your phone. That application sends the same information through the internet to the device clinic, reducing the need for frequent in-clinic visits. You will need access to a smartphone or tablet in order for this technology to work. How is the Study Being Done? Participants in this study will be randomly placed in one of two groups. Neither you, the study staff nor the investigator(s) can influence which group you are in. You will have a 50 % chance of being placed in either the remote management group (RPM) or the standard of care group (SOC). You and the research team will know which group you are in. In the RPM group, you will test out a new remote monitoring application, called VIRTUES, and only do remote transmissions for the duration of the study. In the SOC group, your care will be unaffected and you will simply be followed by our research team. The length of this study for each participant is 18 months.

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab (SOT-R) and rituximab plus chemotherapy (SOT-R+C) or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.